203 related articles for article (PubMed ID: 24842653)
1. The promoter methylation status and mRNA expression levels of CTCF and SIRT6 in sporadic breast cancer.
Wang D; Li C; Zhang X
DNA Cell Biol; 2014 Sep; 33(9):581-90. PubMed ID: 24842653
[TBL] [Abstract][Full Text] [Related]
2. [Promoter methylation and mRNA expression of WT1 gene in MCF10 breast cancer model].
Yang JL; Klinkebiel D; Boland MJ; Tang L; Christman JK
Zhonghua Bing Li Xue Za Zhi; 2007 Apr; 36(4):253-8. PubMed ID: 17706117
[TBL] [Abstract][Full Text] [Related]
3. Promoter hypermethylation of ARID1A gene is responsible for its low mRNA expression in many invasive breast cancers.
Zhang X; Sun Q; Shan M; Niu M; Liu T; Xia B; Liang X; Wei W; Sun S; Zhang Y; Liu XS; Song Q; Yang Y; Ma Y; Liu Y; Yang L; Ren Y; Zhang G; Pang D
PLoS One; 2013; 8(1):e53931. PubMed ID: 23349767
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of CXCL12 mRNA expression by promoter hypermethylation and its association with metastatic progression in human breast carcinomas.
Zhou W; Jiang Z; Liu N; Xu F; Wen P; Liu Y; Zhong W; Song X; Chang X; Zhang X; Wei G; Yu J
J Cancer Res Clin Oncol; 2009 Jan; 135(1):91-102. PubMed ID: 18670789
[TBL] [Abstract][Full Text] [Related]
5. Methylation in the p53 promoter is a supplementary route to breast carcinogenesis: correlation between CpG methylation in the p53 promoter and the mutation of the p53 gene in the progression from ductal carcinoma in situ to invasive ductal carcinoma.
Kang JH; Kim SJ; Noh DY; Park IA; Choe KJ; Yoo OJ; Kang HS
Lab Invest; 2001 Apr; 81(4):573-9. PubMed ID: 11304577
[TBL] [Abstract][Full Text] [Related]
6. Promoter CpG island hypermethylation during breast cancer progression.
Park SY; Kwon HJ; Lee HE; Ryu HS; Kim SW; Kim JH; Kim IA; Jung N; Cho NY; Kang GH
Virchows Arch; 2011 Jan; 458(1):73-84. PubMed ID: 21120523
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic inactivation of BRCA1 is associated with aberrant expression of CTCF and DNA methyltransferase (DNMT3B) in some sporadic breast tumours.
Butcher DT; Rodenhiser DI
Eur J Cancer; 2007 Jan; 43(1):210-9. PubMed ID: 17071074
[TBL] [Abstract][Full Text] [Related]
8. Promoter hypermethylation in ductal carcinoma in situ of the male breast.
Vermeulen MA; van Deurzen CHM; Doebar SC; de Leng WWJ; Martens JWM; van Diest PJ; Moelans CB
Endocr Relat Cancer; 2019 Jun; 26(6):575-584. PubMed ID: 30921768
[TBL] [Abstract][Full Text] [Related]
9. [Promoter methylation and mRNA expression of MCF10 model cell lines of breast cancer].
Yang JL; Klinkebiel D; Boland MJ; Tang L; Christman JK
Zhonghua Bing Li Xue Za Zhi; 2005 Mar; 34(3):177-8. PubMed ID: 15938832
[No Abstract] [Full Text] [Related]
10. Promoter hypermethylation may be an important mechanism of the transcriptional inactivation of ARRDC3, GATA5, and ELP3 in invasive ductal breast carcinoma.
Wang D; Yang PN; Chen J; Zhou XY; Liu QJ; Li HJ; Li CL
Mol Cell Biochem; 2014 Nov; 396(1-2):67-77. PubMed ID: 25148870
[TBL] [Abstract][Full Text] [Related]
11. Frequent epigenetic inactivation of the receptor tyrosine kinase EphA5 by promoter methylation in human breast cancer.
Fu DY; Wang ZM; Wang BL; Chen L; Yang WT; Shen ZZ; Huang W; Shao ZM
Hum Pathol; 2010 Jan; 41(1):48-58. PubMed ID: 19733895
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis.
Borges S; Döppler H; Perez EA; Andorfer CA; Sun Z; Anastasiadis PZ; Thompson E; Geiger XJ; Storz P
Breast Cancer Res; 2013 Aug; 15(2):R66. PubMed ID: 23971832
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic repression of RARRES1 is mediated by methylation of a proximal promoter and a loss of CTCF binding.
Peng Z; Shen R; Li YW; Teng KY; Shapiro CL; Lin HJ
PLoS One; 2012; 7(5):e36891. PubMed ID: 22615834
[TBL] [Abstract][Full Text] [Related]
14. Promoter hypermethylation and post-transcriptional mechanisms for reduced BRCA1 immunoreactivity in sporadic human breast cancers.
Miyamoto K; Fukutomi T; Asada K; Wakazono K; Tsuda H; Asahara T; Sugimura T; Ushijima T
Jpn J Clin Oncol; 2002 Mar; 32(3):79-84. PubMed ID: 11956301
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of Maspin promoter methylation and loss of its protein expression in invasive ductal breast carcinoma: correlation with VEGF-A and MTA1 expression.
Sharma G; Mirza S; Parshad R; Srivastava A; Gupta SD; Pandya P; Ralhan R
Tumour Biol; 2011 Feb; 32(1):23-32. PubMed ID: 20697987
[TBL] [Abstract][Full Text] [Related]
16. [Detection and clinical significance of Notch1 methylation in breast cancer and intraductal proliferative breast lesions].
Zhang N; Sun ZZ; Li F; Cao YW; Zhao CX; Liang WH; Sun HP; Li HA; Fu XG
Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):324-9. PubMed ID: 21756827
[TBL] [Abstract][Full Text] [Related]
17. Lack of RUNX3 inactivation in columnar cell lesions of breast.
Subramaniam MM; Chan JY; Omar MF; Ito K; Ito Y; Yeoh KG; Salto-Tellez M; Putti TC
Histopathology; 2010 Oct; 57(4):555-63. PubMed ID: 20955380
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic progression of columnar cell lesions of the breast to invasive breast cancer.
Verschuur-Maes AH; de Bruin PC; van Diest PJ
Breast Cancer Res Treat; 2012 Dec; 136(3):705-15. PubMed ID: 23104224
[TBL] [Abstract][Full Text] [Related]
19. [Methylation of Runx3 promoter in different breast lesions].
Wang X; Zheng X; Lin X; Shi Y; He Y; Chen G
Zhonghua Bing Li Xue Za Zhi; 2014 Jul; 43(7):447-50. PubMed ID: 25327792
[TBL] [Abstract][Full Text] [Related]
20. Association of Protein Expression and Methylation of DAPK1 with Clinicopathological Features in Invasive Ductal Carcinoma Patients from Kashmir.
Asiaf A; Ahmad ST; Malik AA; Aziz SA; Zargar MA
Asian Pac J Cancer Prev; 2019 Mar; 20(3):839-848. PubMed ID: 30912402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
